Phase 3 trial in 270 participants aged 2-55 with Lennox-Gastaut syndrome: adjunctive soticlestat did not reduce major motor drop seizure frequency vs placebo over 16 weeks (median difference -1.17%; p=.785). Treatment-related adverse events 74.6% vs 68.4%.
RCTn = 270
Guerrini et al. A phase 3, randomized clinical trial of soticlestat as adjunctive therapy for Lennox-Gastaut syndrome